N/A
Completed N=30
rTMS for the Treatment of Freezing of Gait in Parkinson's Disease
Source: ClinicalTrials.gov NCT03219892 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
May 2021
Primary outcomePrimary: Changes of the New Freezing of Gait Questionnaire (NFOGQ) Score — -1.60; -2.13 score on a scale
Summary
This study is a double blind comparative study examining the effectiveness of the rTMS treatment on Freezing of Gait (FOG) in patients with Parkinson's disease (PD). The investigators hypothesize that treatment with rTMS on supplemental motor area will improve gait quality and decrease the frequency of FOG in PD patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Changes of the New Freezing of Gait Questionnaire (NFOGQ) Score |
-1.60; -2.13 | — |
| SECONDARY Motor Subscale of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS Part III) |
-5.79; -0.24 | — |
| SECONDARY Cadence |
2.67; -7.99 | — |
| SECONDARY Turning Duration |
-0.47; 0.59 | — |
| SECONDARY Changes of Brain Functional Connectivity. |
0.33; 0.33; 0.49; 0.50 | — |
Eligibility Criteria
Inclusion Criteria
- Idiopathic PD patients.
- Presenting with FOG.
- The mini-mental state examination questionnaire score above 24 points.
Exclusion Criteria
- Other neurological or psychiatric disorders.
- History of epilepsy, seizures or convulsions.
- Metal implantation.
- History of exposure to rTMS in the past (to minimizing risk of unblinding sham condition).
Data sourced from ClinicalTrials.gov (NCT03219892). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.